Results 181 to 190 of about 4,426,223 (261)

Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development

open access: yesAdvanced Science, EarlyView.
Current SARS‐CoV‐2 vaccines generate short‐lived, strain‐specific immunity. A polymeric TLR7 agonist nanoparticle (TLR7‐NP) adjuvant enhances lymph node targeting and promotes early and sustained germinal center responses toward conserved S2 epitopes of the spike protein.
Sijin Huang   +12 more
wiley   +1 more source

Toxicovigilance in the UK during the COVID-19 pandemic. [PDF]

open access: yesToxicol Res (Camb)
Brooke N   +10 more
europepmc   +1 more source

Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors

open access: yesAdvanced Science, EarlyView.
This study provides an in‐depth analysis of the substrate binding pocket of 3CLpros across all coronavirus species using bioinformatics and structural insights, revealing the critical impact of S2/S4 subsite diversity on the broad‐spectrum activity of approved therapeutics.
Haixia Su   +15 more
wiley   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

open access: yesAdvanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin   +4 more
wiley   +1 more source

Correction: A Patient With Dengue Fever and COVID-19: Coinfection or Not? [PDF]

open access: yesCureus
Malibari AA   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy